多索茶碱与氨茶碱治疗支气管哮喘的临床效果对比观察

Comparison and observation of clinical effect of doxofylline and amino-phylline treating bronchial asthma

目的比较多索茶碱与氨茶碱治疗支气管哮喘的效果。方法选取2013年11月-2014年11月来本院治疗的支气管哮喘的患者160例,随机将其均匀分成两组,对照组给予氨茶碱治疗,治疗组给予多索茶碱治疗。比较两组的治疗效果、不良反应发生率、肺功能等。结果治疗组的总有效率为97.50%,明显高于对照组的88.75%,不良反应发生率为5.00%,明显低于对照组的25.00%（P〈0.05）;治疗组治疗后的FEV1%为（82.41±8.81）%,对照组为（73.02±4.71）%,治疗组患者的肺功能改善情况明显好于对照组（P〈0.05）;治疗组对治疗的满意率为97.50%,明显高于对照组的85.00%（P〈0.05）。结论多索茶碱治疗支气管哮喘可增强患者的肺功能,提高治疗有效率,减少不良反应的发生,保证用药安全性,治疗效果得到患者的充分肯定以及好评。多索茶碱是一种治疗支气管哮喘的特效药,临床意义显著,值得临床推广。

Objective To compare the effect of doxofylline and aminophylline treating bronchial asthma. Methods 160 patients with bronchial asthma treated in our hospital from November 2013 to November 2014 were selected and they were randomly and evenly divided into two groups.Control group was treated with aminophylline,while the treatment group was treated with doxofylline.Treatment effect,the incidence rate of adverse reaction,lung function and so on be-tween two groups was compared respectively. Results The total effective rate in treatment group （97.50%） was signifi-cantly higher than that of control group （88.75%）,and the incidence rate of adverse reaction in treatment group （5.00%） was significantly lower than that of control group （25.00%） （P〈0.05）;FEV1% was （82.41±8.81）% in treatment group after treatment,and it was （73.02±4.71）% in control group,improvement of pulmonary function of patients in treatment group was better than that of control group （P〈0.05）;the satisfaction rate for treatment in in treatment group （97.50%） was sig-nificantly lower than that of control group （85.00%） （P〈0.05）. Conclusion Doxofylline treating bronchial asthma can en-hance the pulmonary function of the patients,and improve the effective rate of treatment,and reduce the occurrence of adverse reaction to ensure the safety of medication and treatment effect is fully affirmed and praised by patients.Doxo-fylline is an effective medicine in the treatment of bronchial asthma,clinical significance is significant,and it is worthy of clinical promotion.